ライフサイエンスコーパス: bladder tumor

1 a molecular clock to determine the age of a bladder tumor.

2 nts that commonly cooccur in muscle invasive bladder tumors.

3 her neoantigen-reactive TILs can be found in bladder tumors.

4 fied based on its overexpression in invasive bladder tumors.

5 in induction of apoptosis preferentially in bladder tumors.

6 storing IFN sensitivity in a subset of human bladder tumors.

7 aled in cells derived from the most advanced bladder tumors.

8 recursor of low-grade, superficial papillary bladder tumors.

9 lasia and superficial papillary non-invasive bladder tumors.

10 e INK4A gene occur frequently in superficial bladder tumors.

11 retinoic acid and etretinate) in superficial bladder tumors.

12 so may be a late event in the development of bladder tumors.

13 10 bladder cancer cell lines and 14 primary bladder tumors.

14 and lacking p16(INK4A), develop early-onset bladder tumors.

15 nrichment with APOBEC-signature mutations in bladder tumors.

16 ach prolonged survival of mice bearing human bladder tumors.

17 6% in diagnosing both early- and polyp-stage bladder tumors.

18 notably ERCC2 mutations present in 10-15% of bladder tumors.

19 tures of surgical specimens of human patient bladder tumors.

20 tion of AR-CD44 expression observed in human bladder tumors.

21 rothelial cells gave rise to muscle-invasive bladder tumors.

22 for PET imaging of galectin-1-overexpressing bladder tumors.

23 ct GLI1 were found in resected human primary bladder tumors.

24 63 acting as an oncogene in certain invasive bladder tumors.

25 re that is strongly associated with invasive bladder tumors.

26 as done to determine mRNA expression from 96 bladder tumors.

27 ethylation at certain genes in both lung and bladder tumors.

28 tegies have been studied in the treatment of bladder tumors.

29 te cancer xenografts and established UM-UC-3 bladder tumors.

30 ethylation and loss of expression in primary bladder tumors.

31 r more effective cell death across different bladder tumors.

32 against targets differentially expressed in bladder tumors.

33 of aggressive clinical behavior in advanced bladder tumors.

34 atients initially diagnosed with early-stage bladder tumors (14 with nonprogressive disease and 15 wi

35 ed to analyze the transcript profiles of 105 bladder tumors: 33 superficial, 72 invasive lesions, and

36 TXAS is overexpressed in common forms of bladder tumors: 69 of 97 (71.1%) transitional cell carci

37 ly and more extensively in UTT (94%) than in bladder tumors (76%; P < .0001).

38 hance bladder surveillance and transurethral bladder tumor, a purpose-specific robotic system for LES

39 complete genome analysis, we sequenced five bladder tumors accrued from patients with muscle-invasiv

40 ceived no LT, transurethral resection of the bladder tumor alone, or < 50 Gy of radiation therapy del

41 s is both necessary and sufficient to induce bladder tumors along a low-grade, noninvasive papillary

42 In the present study RB negative bladder tumors also exhibited strong nuclear p16 stainin

43 A transurethral resection of the bladder tumor and biopsy identified transitional cell ca

44 we have carried out mutation analysis of 62 bladder tumors and 33 bladder tumor-derived cell lines t

45 f nuclear myopodin expression could classify bladder tumors and bladder cancer cell lines based on th

46 Kalpha plays a role in the aggressiveness of bladder tumors and constitutes a new approach for bladde

47 ir combined expression was shown to stratify bladder tumors and define squamous differentiation.

48 cificity and sensitivity in the detection of bladder tumors and extravesical disease relative standar

49 was also hypermethylated in 11 of 16 primary bladder tumors and in 3 of 4 primary colon tumors when c

50 ) biopsies that represented both superficial bladder tumors and invasive bladder cancers.

51 T cells from human bladder tumors and non-malignant tissue were assessed wi

52 ease stratification and outcome prognosis in bladder tumors and noninvasive diagnosis in urinary samp

53 cle progression may prove useful for staging bladder tumors and suggest a tumor suppressor role of my

54 a better understanding of LOI, we studied 41 bladder tumors and their adjacent normal bladder mucosa.

55 78 are down-regulated in prostate, colon and bladder tumors, and human cancer cell lines.

56 capable of synergizing with Ha-ras to induce bladder tumors; and that the complete loss of p53 is a p

57 bitor of angiogenesis, in the development of bladder tumor angiogenesis.

58 RECENT FINDINGS: Strategies including bladder tumor antigen assay, NMP22, ImmunoCyt, and UroVy

59 Bladder tumors are characterized by markedly increased a

60 Cell-free extracts of muscle-invasive bladder tumors are defective in nonhomologous end-joinin

61 d that growth rates for ectopic melanoma and bladder tumors are increased in Adora2a(-/-) mice within

62 ty that recurrences of low-grade superficial bladder tumors are related to the continuing presence of

63 upports the hypothesis that male rat urinary bladder tumors arise through urinary bladder calculi for

64 The bladder tumor-associated hyaluronidase activity is disti

65 on increased incidences of male rat urinary bladder tumors at high exposure levels and on female mou

66 Gene profiling successfully classified bladder tumors based on their progression and clinical o

67 hemotherapy after transurethral resection of bladder tumor before and after publication of a randomiz

68 ortant in understanding pathways critical to bladder tumor biology.

69 e variants by screening genomic DNA of human bladder tumors, bladder cancer cell lines, and normal bl

70 In bladder tumor blood vasculature, the secreted factor ang

71 istory of pelvic RT were classified into the bladder tumor (BT) group.

72 orphism at codon 88 was noted in one primary bladder tumor, but no other abnormalities were found, su

73 logically valid approach in patients without bladder tumors, but is limited by technical consideratio

74 ene in several lethal tumor types, including bladder tumors, but its role as a pathogenic driver has

75 curate, label-free, noninvasive diagnosis of bladder tumors by analyzing nano-biomarkers in a single

76 p53exons 4-9 were amplified from 146 bladder tumors by PCR, screened by single-strand conform

77 in the development of low-grade superficial bladder tumors by using a heterotopically transplanted r

78 intravesical administration of these agents, bladder tumors can be detected using fluorescence cystos

79 Bladder tumors can present with gross or microscopic hem

80 es unique patterns of gene expression during bladder tumor cell differentiation.

81 n human fibroblast cells (LD419) and a human bladder tumor cell line (T24).

82 e mismatch repair to the mutant extract, the bladder tumor cell line is likely to be defective in an

83 12-myristate 13-acetate treatment of the T24 bladder tumor cell line resulted in a time- and dose-dep

84 Analysis of the T24 bladder tumor cell line reveals a functional autocrine l

85 G1 cell cycle arrest by 5-Aza-CdR in the T24 bladder tumor cell line were also heritable after prolon

86 Migrating NBT-II cells (a rat bladder tumor cell line) were microinjected with the cag

87 -hexanoyl-D-sphingosine, in an Rb-null human bladder tumor cell line, 5637, as well as in retrovirall

88 Experiments on the human bladder tumor cell line, HT1376, showed that exisulind i

89 In bladder tumor cell lines derived from aggressive carcino

90 Here we find that 11 out of the 14 bladder tumor cell lines examined express one or more VE

91 Analysis of a panel of 33 bladder tumor cell lines revealed regions of contiguous

92 nvolved in the survival and proliferation of bladder tumor cells as well as other tumor cell types.

93 Here, we showed that bladder tumor cells expressing the collagen receptor, CD

94 in A was evident in its inhibitory growth of bladder tumor cells in a nude mice model (57% of inhibit

95 ntly higher urine TRAIL levels, which killed bladder tumor cells in vitro versus nonresponders.

96 Comparative transcriptomic analysis of bladder tumor cells isolated from PDXs indicates unique

97 t coculture of murine bone marrow cells with bladder tumor cells promoted strong expression of PD-L1

98 d the fate of DBCCR1-expressing cells, human bladder tumor cells were transiently transfected with an

99 ive phenotype was similarly observed in 253J bladder tumor cells, in which Sod expression resulted in

100 ChoKalpha is constitutively altered in human bladder tumor cells.

101 e inhibitors (HDACi) against TRAIL-resistant bladder tumor cells.

102 MT) that combines transurethral resection of bladder tumor, chemotherapy for radiation sensitization,

103 Due to bladder tumors' contact with urine, urine-derived cells

104 tumor grade and overall patient survival in bladder tumors contained in tissue microarrays.

105 utation analysis of 62 bladder tumors and 33 bladder tumor-derived cell lines to establish the freque

106 The bladder tumor-derived hyaluronidase present in CM and pa

107 The identification of bladder tumor-derived hyaluronidase should help in eluci

108 nd in the partially purified preparations of bladder tumor-derived hyaluronidase.

109 In this study, we characterized the bladder tumor-derived hyaluronidase.

110 stoscopy is a promising technique for use in bladder tumor detection of lesions larger than 5 mm.

111 Mice were implanted with human 253J-BV bladder tumors (EGF+) or human SN12-PM6 renal tumors (EG

112 enetic alterations seen in 178 patients with bladder tumors (either muscle-invasive or non-muscle-inv

113 Herein we show that BCG-induced bladder tumor elimination requires CD4 and CD8 T cells,

114 is resistant to progression to full-fledged bladder tumors even in the absence of Ink4a/Arf.

115 The fact that phenotypically different bladder tumors exhibit different patterns of cell cycle

116 and genetically engineered mouse models and bladder tumor explants.

117 ASS1 expression status in bladder tumors from 183 Caucasian and 295 Asian patients

118 However, compared to other tumors, bladder tumors from both exposed and unexposed individua

119 which it is possible to differentiate human bladder tumors from normal bladder epithelial cells.

120 frequency and pattern of p53 mutations in 34 bladder tumors from people with high-level occupational

121 tional exposure to arylamines to those in 30 bladder tumors from people without such exposure.

122 Analysis of bladder tumors from UPPA mice demonstrates that mA3 prom

123 murine VEGFR-2, on orthotopic human 253J-BV bladder tumors growing in nude mice.

124 activity of other dietary components against bladder tumor growth and metastasis.

125 Curcumin also decreased bladder tumor growth in athymic nude mice bearing KU7 ce

126 ata suggest that soy isoflavones can inhibit bladder tumor growth through a combination of direct eff

127 , HYAL-v1 expression may negatively regulate bladder tumor growth, infiltration, and angiogenesis.

128 curring in SV40T transgenic mice) to promote bladder tumor growth.

129 ipt of subsequent transurethral resection of bladder tumor >3 months after index diagnosis of NMIBC a

130 A second group (two bladder tumors) had no chromothripsis, and a simpler gen

131 ermine the aggressive clinical course of the bladder tumors harboring both p53 and pRB alterations.

132 Basal and luminal subtypes of invasive bladder tumors have significant prognostic and predictiv

133 meta-dataset of high-grade, muscle-invasive bladder tumors identified two intrinsic, molecular subse

134 Detailed genetic analyses of HGT1 bladder tumors identify features that correlate with out

135 istered orally) and against human breast and bladder tumors implanted in nude mice.

136 Clinically, ATDC was highly expressed in bladder tumors in a manner associated with invasive grow

137 m mice with implanted syngeneic tumors (MBT2 bladder tumors in C3H mice, Renca kidney, and CT26 colon

138 arin was shown to produce a low incidence of bladder tumors in rats if administered in a two-generati

139 C-DIMs on bladder cancer cells in vitro and bladder tumors in vivo.

140 th the advanced diseases, and their roles in bladder tumor initiation and in synergizing with oncogen

141 In vivo, ATDC is required for TP63-induced bladder tumor invasion and metastasis.

142 nance (I+M) after transurethral resection of bladder tumor is standard of care (SOC) in high-risk non

143 HLA-ABC expression by bladder tumors is progressively diminished as disease pr

144 th factor receptor 3 (FGFR3) are frequent in bladder tumors, little information is available on their

145 In the neoadjuvant group, a better bladder tumor local control and a significant improvemen

146 cancer diagnosis and patient perspectives on bladder tumor markers.

147 Using a murine bladder tumor (MB49), which we show to express the male

148 xpressed on dendritic cells (DCs) within the bladder tumor microenvironment of orthotopic bladder can

149 y and induces pharmacodynamic effects in the bladder tumor microenvironment, including a reduction in

150 f patients with NMIBC as a surrogate for the bladder tumor microenvironment.

151 This orthotopic human bladder tumor model also provides a clinically relevant

152 In this study, we report a transgenic mouse bladder tumor model upon induction of constitutively act

153 as investigated in vivo in an orthotopic rat bladder tumor model.

154 Using humanized immunocompetent orthotopic bladder tumor models, we demonstrate the ability to ther

155 sease in murine B16/F10.9 melanoma and MBT-2 bladder tumor models.

156 at second look after transurethral resection bladder tumor, most still require radical cystectomy.

157 extended our methylation studies to resected bladder tumors (n = 128) and exfoliated cell samples (bl

158 samples (n = 25), and tissue microarrays of bladder tumors (n = 173).

159 tochemistry of tissue microarrays containing bladder tumors (n = 173).

160 hemistry using tissue microarrays of primary bladder tumors (n = 193 cases).

161 ive information by stratifying patients with bladder tumors (n = 37) based on their overall survival

162 cell lines (n = 28) and a cohort of primary bladder tumors (n = 98).

163 In bladder tumors, NKG2A is acquired on CD8(+) T cells late

164 man tumor types (N = 1,630 samples) and with bladder tumors of different stages and grades (N = 144 s

165 ectomy specimens and was verified in urinary bladder tumors of various pathogenetic subsets with long

166 gene expression profiles of 23 primary human bladder tumors of various stages and grades, and then we

167 e tumors with 82.2% accuracy, and stratified bladder tumors on the basis of clinical outcome.

168 lgorithms were used to classify and stratify bladder tumors on the basis of stage, node metastases, a

169 poptosis resistance and are overexpressed in bladder tumors, our data suggest that flavokawain A may

170 es involved and by the extent of the primary bladder tumor (p stage).

171 We also identified a bladder tumor patient carrying a germ-line mutation but

172 e found in the urine of normal and low-grade bladder tumor patients, the urine of high-grade bladder

173 dergoing complete transurethral resection of bladder tumor, patients received either sequential intra

174 risk population of patients with superficial bladder tumors, patients who have p53 nuclear overexpres

175 The detection of high-grade bladder tumors prior to invasion is crucial for a good p

176 ts cofactors, and have a pivotal role in the bladder tumor progression and the regulation of stem-lik

177 xpression of which inversely correlates with bladder tumor progression, demonstrating the usefulness

178 idase should help in elucidating its role in bladder tumor progression.

179 e, suggesting their potential involvement in bladder tumor progression.

180 S) and which gene pathways are important for bladder tumor progression.

181 ative advantage that plays a key role during bladder tumor progression.

182 NMIBC and initial transurethral resection of bladder tumor), progression (defined as receipt of defin

183 y were categorized into radiation-associated bladder tumor (RA-BT) group, whereas 33 patients diagnos

184 Although 34 of 36 lines aligned to bladder tumors rather than other histologies, only 16 of

185 As over two-thirds of bladder tumors recur, vigilant surveillance is required.

186 skewing toward type 2 immunity, may predict bladder tumor recurrence and influence the mortality of

187 thout intravesical therapy), the superficial bladder tumor recurrence rate is 30% to 70% within 12 mo

188 Twenty-four patients (56%) developed bladder tumor recurrences from 5 to 96 months, which wer

189 treatment after transurethral resection of a bladder tumor, recurrences and progression remain a prob

190 Trimodality therapy with transurethral bladder tumor resection and cisplatin-based chemoradiati

191 %, or 81% reduction in the volume of 253J-BV bladder tumors, respectively, and 26%, 23%, or 51% reduc

192 ceived a redo transurethral resection of the bladder tumor (reTURBT).

193 ptional characterizations of mouse and human bladder tumors revealed a significant overlap and confir

194 r cancer cells, paired normal urothelium and bladder tumor samples (n = 25), and tissue microarrays o

195 ncreased PSCA mRNA expression in two sets of bladder tumor samples (n = 36, P = 0.0007 and n = 34, P

196 djuvant cisplatin-based chemotherapy primary bladder tumor samples from 30 muscle-invasive bladder ca

197 2 inhibitors are generating interest because bladder tumors seem to contain higher concentrations of

198 Invasive bladder tumors showed decreased nuclear myopodin express

199 e cancers, the majority of transitional cell bladder tumors showed Id1 protein expression in both tum

200 potential foundation for the development of bladder tumor-specific oncolytic viral therapies.

201 We analyzed five bladder tumor specimens using whole-slide mFISH imaging

202 Pre-NAC transurethral bladder tumor specimens were sequenced for mutations in

203 cal analysis was conducted in a series of 50 bladder tumor specimens, including 3 metastatic lymph no

204 une cells isolated from syngeneic mouse MB49 bladder tumors, spleens, and tumor-draining lymph nodes

205 affect prognosis independent of the primary bladder tumor stage.

206 However, during a search for candidate bladder tumor suppressor genes within the 9q34 region of

207 ising the possibility that this represents a bladder tumor suppressor.

208 at Cd24a-deficient male mice developed fewer bladder tumors than C57BL/6 control male mice.

209 he p53 knockout mice, results in early-onset bladder tumors that are either low-grade superficial pap

210 ring of CNAs defined two distinct classes of bladder tumors that differed in the degree of their CNA

211 nsiveness to PD-L1 blockade immunotherapy in bladder tumors that have high abundance of CD8(+) T cell

212 ctive markers of the biological potential of bladder tumors that will enable identification of those

213 ns to treat low-grade, superficial papillary bladder tumors, the most common tumor in the urinary sys

214 agnosis and management of nonmuscle-invasive bladder tumors, the risk of both recurrence and progress

215 proximately 20% of patients with superficial bladder tumors, the tumors progress to invasive tumors a

216 For detection of bladder tumors, there was higher sensitivity for the UP

217 y remains the gold standard for diagnosis of bladder tumors, though fluorescent light and urinary bio

218 he HA levels are also elevated (3-5-fold) in bladder tumor tissues (P < 0.001).

219 estored ferroptosis sensitivity of xenograft bladder tumor tissues harboring KDM6A mutation.

220 In human bladder tumor tissues, the frequency and intensity of SP

221 are expressed in normal tissues/cells and G1 bladder tumor tissues.

222 synergizes with chemotherapy and sensitizes bladder tumors towards anti-PD1 immune checkpoint inhibi

223 Transurethral resection of bladder tumor (TURBT) is the initial staging procedure f

224 ed-modality therapy (transurethral resection bladder tumor [TURBT], radiation therapy, chemotherapy)

225 ring a procedure (transurethral resection of bladder tumors [TURBT] or office biopsy) by more than 50

226 rrently performed transurethral resection of bladder tumor-TURP seems oncologically acceptable (in se

227 er profiles were characterized in 41 primary bladder tumors using array-based comparative genomic hyb

228 ression profiles of early-stage and advanced bladder tumors using cDNA microarrays containing 17,842

229 When comparing 15 primary bladder tumors versus a pool of four bladder cancer cell

230 der cancer model, curcumin alone reduced the bladder tumor volume, but a significantly greater reduct

231 An integrative analysis of 97 high-grade bladder tumors was conducted to identify actionable drug

232 Cyclin E protein expression analyzed in 265 bladder tumors was increased in aggressive tumors (P = 0

233 In both NMSC and bladder tumors we found a high prevalence of EMAST (75.4

234 Thus, bladder tumors were characterized by changes in miRNA ex

235 dies, 88% to 100% of mice bearing orthotopic bladder tumors were cured after four intravesical treatm

236 (100%) urine DNA samples from patients with bladder tumors were found to have 24 or more single-nucl

237 ATDC-driven bladder tumors were indistinguishable from human bladder

238 splicing variant, were found in the panel of bladder tumors while no mutation was observed in the ren

239 The majority of patients with invasive bladder tumors who achieve T0 status after neoadjuvant M

240 Patients with high-risk superficial bladder tumors who are treated successfully by a bladder

241 elation with overall survival in a subset of bladder tumors whose follow-up was available (n = 69).

242 for definitive local therapy of his primary bladder tumor with radical cystectomy or radiation.

243 he Drosophila patched gene (PTC), 20 primary bladder tumors with chromosome 9q LOH were screened for

244 Furthermore, we found that bladder tumors with HRAS- or NRAS-activating mutations w

245 tion of the second inactivation event in six bladder tumors with LOH of 10q implies that the PTEN/MMA

246 In a sample of bladder tumors with wild-type p53, elevated expression o

247 These bladder tumors, with impaired Notch signaling, also show

248 eutic activity of CD40 agonism in orthotopic bladder tumors, with upregulation of transpresented IL-1

249 e-occurring low-grade, superficial papillary bladder tumors, without eliciting invasive carcinomas.

250 has been linked to the invasive phenotype in bladder tumors yet a primary role for N-cadherin in inva